Tag: Praxbind

Pradaxa dabigatran etexilate manufacture

Final Phase III results support safety of idarucizumab as reversal agent...

Final results from RE-VERSE AD study show that idarucizumab, marketed in the US as Praxbind (Boehringer Ingelheim), was able to immediately reverse the anticoagulant...

Boehringer Ingelheim launches RE-VECTO global programme to explore idarucizumab use in...

Boehringer Ingelheim has announced the launch of its global RE-VECTO programme for idarucizumab (Praxbind), the specific reversal agent for dabigatran etexilate (Pradaxa). Idarucizumab is approved...